<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **SARC-E 1 of 6** Internal request: Include trabectedin for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen. | Based on the data in the noted reference, the panel consensus was to add trabectedin (category 2A) for treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have received a prior anthracycline-containing regimen.  
| **SARC-E 2 of 6** External request: Submission from Columbia University requesting the NCCN Sarcoma Guideline Panel to review the enclosed data for inclusion of Palbociclib (PD0332991) in the NCCN guidelines for treatment of patients with well-differentiated and de-differentiated liposarcoma (WD-DDLS). | Based on the data in the noted reference(s), the panel consensus was to add palbociclib (category 2A) for treatment of patients with well-differentiated and de-differentiated liposarcoma (WD-DDLS).  
3. Kovatcheva M, Liu DD, Dickson MA, Klein ME, O’Connor R, Wilder FO, | YES | NO | ABSTAIN | ABSENT |